Kesatuan Eropah - Itali - EMA (European Medicines Agency)

biogen netherlands b.v.  - fampridine - sclerosi multipla - altri farmaci sul sistema nervoso - fampyra è indicato per il miglioramento della deambulazione nei pazienti adulti con sclerosi multipla con disabilità motoria (expanded disability status scale 4-7).

Kesatuan Eropah - Itali - EMA (European Medicines Agency)

biogen netherlands b.v. - natalizumab - sclerosi multipla - immunosoppressori selettivi - tysabri is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis for the following patient groups: , patients with highly active disease activity despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 e 5. 1), , or, patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain mri or a significant increase in t2 lesion load as compared to a previous recent mri.

Switzerland - Itali - Swissmedic (Swiss Agency for Therapeutic Products)

sanofi-aventis (suisse) sa - teriflunomidum - compresse rivestite con film - teriflunomidum 14 mg, colore.: e 132, excipiens pro compresso haze. - traitement des patients adultes et des patients pédiatriques de 10 ans et plus présentant des formes récurrentes-rémittentes de sclérose en plaques (sep) - synthetika

Switzerland - Itali - Swissmedic (Swiss Agency for Therapeutic Products)

biogen switzerland ag - dimethylis fumaras - capsule rigide gastroresistenti - dimethylis fumaras 120 mg, carmellosum natricum conexum, cellulosum microcristallinum, magnesii stearas, talcum, silica colloidalis anhydrica, acidi methacrylici et methylis methacrylatis polymerisatum 1:1, Überzug: acidi methacrylici et ethylis acrylatis polymerisati 1:1 dispersio 30 per centum, polysorbatum 80, natrii laurilsulfas, triethylis citras, talcum, simeticonum, kapselhülle: gelatina, e 171, e 172 (flavum), e 133, drucktinte: lacca, kalii hydroxidum, e 172 (nigrum), pro capsula corresp. natrium 1.37 mg. - multiple sklerose - synthetika

Switzerland - Itali - Swissmedic (Swiss Agency for Therapeutic Products)

biogen switzerland ag - dimethylis fumaras - capsule rigide gastroresistenti - dimethylis fumaras 240 mg, carmellosum natricum conexum, cellulosum microcristallinum, silica colloidalis anhydrica, magnesii stearas, acidi methacrylici et methylis methacrylatis polymerisatum 1:1, Überzug: acidi methacrylici et ethylis acrylatis polymerisati 1:1 dispersio 30 per centum, natrii laurilsulfas, triethylis citras, polysorbatum 80, talcum, simeticonum, kapselhülle: gelatina, e 171, e 172 (flavum), e 133, drucktinte: lacca, kalii hydroxidum, e 172 (nigrum), pro capsula corresp. natrium 1.69 mg. - multiple sklerose - synthetika

Switzerland - Itali - Swissmedic (Swiss Agency for Therapeutic Products)

merck (schweiz) ag - cladribinum - compresse - cladribinum 10.00 mg, hydroxypropylbetadexum, sorbitolum 64.04 mg, magnesii stearas, pro compresso. - multiple sklerose - synthetika

Switzerland - Itali - Swissmedic (Swiss Agency for Therapeutic Products)

biogen switzerland ag - fampridinum - retardtabletten - fampridinum 10 mg, cellulosum microcristallinum, hypromellosum, silica colloidalis anhydrica, magnesii stearas, Überzug: hypromellosum, macrogolum 400, titanii dioxidum, pro compresso obducto. - multiple sklerose - synthetika

Kesatuan Eropah - Itali - EMA (European Medicines Agency)

accord healthcare s.l.u. - fampridine - sclerosi multipla - altri farmaci sul sistema nervoso - fampridine accord is indicated for the improvement of walking in adult patients with multiple sclerosis with walking disability (edss 4-7).

Switzerland - Itali - Swissmedic (Swiss Agency for Therapeutic Products)

biogen switzerland ag - diroximeli fumaras - magensaftresistente hartkapseln - diroximeli fumaras 231 mg, acidi methacrylici et ethylis acrylatis polymerisatum 1:1, crospovidonum, cellulosum microcristallinum, silica colloidalis anhydrica, triethylis citras, talcum, magnesii stearas, kapselhülle: hypromellosum, e 171, kalii chloridum, carrageenanum, aqua, drucktinte: lacca, propylenglycolum, ammoniae solutio 30 per centum, e 172 (nigrum), kalii hydroxidum pro capsula. - vumerity ist für die behandlung von patienten mit schubförmig remittierend verlaufender multipler sklerose (ms) zur reduzierung der schubhäufigkeit indiziert. - synthetika

Kesatuan Eropah - Itali - EMA (European Medicines Agency)

biogen netherlands b.v. - diroximel fumarate (biib098) - sclerosi multipla recidivante-remittente - immunosoppressori - vumerity is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (see section 5. 1 for important information on the populations for which efficacy has been established).